Low intensity stimulation of aortic baroreceptor afferent fibers as a potential therapeutic alternative for hypertension treatment

Ibrahim M. Salman1,2,*, Omar Z. Ameer3, Sheridan McMurray3, Sarah F. Hassan3, Arun Sridhar3, Stephen J. Lewis2,4 & Yee-Hsee Hsieh5

Carotid baroreceptor stimulation has been clinically explored for antihypertensive benefits, but neuromodulation of aortic baroreceptor afferents remains unexplored for potential translation into the clinic. Published studies have used supramaximal stimulations, which are unphysiological and energy inefficient. The objective of the present study was to identify optimal low-charge nerve stimulation parameters that would provide a clinically-relevant (20–30 mmHg) decrease in mean arterial pressure (MAP) in anesthetized spontaneously hypertensive rats. Stimulations of 20 s were delivered to the left aortic depressor nerve (ADN) of these rats using low ranges of pulse amplitudes (≤ 0.6 mA), widths (≤ 0.5 ms) and frequencies (≤ 5 Hz). We also assessed the effects of continuous (20 s) versus intermittent (5 s ON/3 s OFF and 5 s ON/3 s OFF for 20 s) stimulation on MAP, heart rate (HR), mesenteric (MVR) and femoral (FVR) vascular resistance using low (5 Hz) and high (15 Hz) frequencies. Lower pulse amplitudes (0.2 mA) produced 9 ± 2 to 18 ± 2 mmHg decreases in MAP. Higher pulse amplitudes (0.4 mA) produced a median MAP reduction of 28 ± 4 mmHg at 0.2 ms and 5 Hz, with no added benefit seen above 0.4 mA. Continuous and intermittent low frequency stimulation at 0.4 mA and 0.2 ms produced similar sustained decreases in MAP, HR, MVR and FVR. Continuous high frequency stimulation at 0.4 mA and 0.2 ms produced larger reductions in MAP, HR, MVR and FVR compared with all low frequency and/or intermittent high frequency stimulations. We conclude from these findings that “low intensity intermittent” electrical stimulation is an effective alternate way for neuromodulation of the aortic baroreceptor afferents and to evoke a required restoration of MAP levels in spontaneously hypertensive rats. This approach enables low energy consumption and markedly lowers the excessive decreases in MAP and hemodynamic disturbances elicited by continuous high-charge injection protocols.

Chronic hypertension affects more than one billion people worldwide1 and is a major risk factor for sudden cardiac death2. This common clinical condition increases the risk for heart disease and stroke, both of which are leading causes of morbidity and mortality in this patient population1. Currently, dietary modification, salt restriction, regular exercise and antihypertensive medications remain the treatment(s) of choice for hypertensive subjects4. However, resistant hypertensive patients, who fail to adequately respond to available treatment options, remain under-treated and therefore highly predisposed to increased risk of cardiovascular events. As a result, there is still a persistent need for novel therapeutic strategies aimed at for instance, lowering sympathetic nerve activity (SNA), to decrease arterial blood pressure (ABP) within the hypertensive population.

1Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh 12714, Saudi Arabia. 2Division of Pulmonology, Allergy and Immunology, Department of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 3Galvani Bioelectronics, Stevenage, Hertfordshire, UK. 4Electrical Stimulation Center, Case Western Reserve University, Cleveland, OH, USA. 5Division of Pulmonary, Critical Care, and Sleep Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. *email: isalman@alfaisal.edu
In the recent years, device-based neurostimulation has gained popularity as a novel means to control hypertension. This intervention alters central autonomic drive by directly enhancing the activity of baroreceptor afferent neurons, a set of nerve fibers that are frontline sensors that respond to fluctuations in ABP and relay this information directly to the nucleus tractus solitarius (NTS) in the brainstem, which in turn sends information to other cardiovascular control centers within the brainstem and higher regions. The results of activating baroafferents include inhibition of sympathetic drive to the heart and vasculature and increased vagal parasympathetic drive to the heart, which together translate into decreases in peripheral vascular resistances, cardiac output, heart rate and therefore ABP. The overall process mimics spontaneous activation of the baroreceptor reflex, albeit bypassing the process of ABP-induced activation of mechanosensitive baroreceptors in the carotid sinus and the aortic arch. This therefore enables a defined control of afferent input into the central nervous system (CNS) and fine-tunes the magnitude of ABP drop. Indeed, baroreflex activation therapy (BAT) targeting the carotid sinus, via the implantable first-generation Rheo Hypertension Therapy System and then the second-generation Barostim Neo, has produced sustained decreases in SNA and ABP in humans, with some preclinical and controlled clinical trials having been undertaken to grant the devices approval to treat patients with resistant hypertension. Available data on this innovative treatment approach indicate that there is an urgent need to improve the safety and efficacy profiles. For instance, published experimental and clinical studies employ large current/voltage amplitudes, longer pulse widths or ultrahigh frequencies during electrical stimulation. These highly energy inefficient neuro-modulation methods, which in some cases lead to excessive decreases in ABP, and which compromise the efficacy and the longevity of this stimulation paradigms, warrant further research studies that are designed to optimize the charge parameters.

Although carotid baroreceptor stimulation has been clinically explored for antihypertensive benefits, aortic baroreceptor afferents modulation, on the other hand, remains untouched for clinical translation. Published evidence suggests that aortic baroreceptors and their afferent fibers display higher pressure sensitivity than carotid baroreceptors, possibly due to the more important functional role they play in control and maintenance of systemic ABP. This potentially makes the aortic baroreceptors a superior novel neural target for ABP modulation and therefore an important alternative avenue for therapeutic intervention in hypertension.

Direct electrical stimulation of the baroreceptor reflex arc in spontaneously hypertensive rats (SHR), via activation of baroreceptor afferents within the aortic depressor nerve (ADN), may bring in novel ways of developing and enhancing BAT by providing a safe and effective stimulus paradigm. Our main goal was therefore to investigate the aortic baroreceptor afferent stimulation in SHR as a viable target for ABP modulation and to identify optimal minimal charge stimulation parameters that would provide a clinically relevant drop in mean arterial pressure (MAP) of 20 – 30 mmHg as reported previously.

Results

Study 1: Optimization of ADN stimulation parameters. Baseline MAP of the SHR used in these studies was 174 ± 6 mmHg. The effect of modifying pulse width, amplitude, and frequency of ADN stimulation on MAP of SHRs is shown in Fig. 1.

A robust frequency-dependent depressor response was seen at all pulse amplitudes and widths used (P < 0.05 for all responses). Lower pulse amplitudes of 0.2 mA produced an average decrease in MAP of 9 ± 2 to 18 ± 2 mmHg at all pulse widths tested. Higher pulse intensity of 0.4 mA produced the largest decrease in MAP at 5 Hz stimulation frequency, with a median MAP reduction of 28 ± 4 mmHg seen at a pulse width of 0.2 ms. Higher pulse amplitude of 0.6 mA resulted in relatively similar drops in MAP to that of the 0.4 mA at all pulse widths and frequencies tested.

Study 2: Effect of continuous versus intermittent stimulation of the ADN using low (5 Hz) and high (15 Hz) stimulation frequency. Baseline hemodynamics prior to the 5 Hz and 15 Hz stimulation protocols are presented in Table 1. There was no baseline shift in the measured variables prior to each stimula-
5 s ON/3 s OFF = 70 ± 7 s

enced by the mode of stimulation or the frequency of the stimulus (5 Hz: continuous = 62 ± 6 s overall MAP recovery time from when the stimulus was applied until it was completely turned off was not influenced by the mode of stimulus delivery, both 5 Hz and 15 Hz stimulations significantly lowered MAP, HR, MBF, MVR and FVR relative to baseline. Reflex FBF, by contrast, was higher compared with baseline values.

A representative raw data trace illustrating the effects of continuous and intermittent stimulation of the ADN using 5 Hz and 15 Hz stimulation frequencies in one SHR is shown in Fig. 2.

At 5 Hz, peak depressor responses to ADN stimulation (Fig. 3) and total AUC (Table 2) were similar regardless of whether the stimulation was delivered continuously or intermittently. At 15 Hz, on the other hand, lower drops in MAP (Fig. 3) and/or relatively smaller AUC values (Table 2) were observed when stimulation was intermittent as opposed to continuous. Comparing low versus high frequency data, continuous and intermittent stimulation at 15 Hz produced larger MAP reductions and/or AUC measures compared with respective stimulations at 5 Hz. Overall MAP recovery time from when the stimulus was applied until it was completely turned off was not influenced by the mode of stimulation or the frequency of the stimulus (5 Hz: continuous = 62 ± 6 s versus intermittent 5 s ON/3 s OFF = 70 ± 7 s versus intermittent 5 s ON/5 s OFF = 62 ± 6 s; and 15 Hz: continuous = 67 ± 8 s versus intermittent 5 s ON/3 s OFF = 70 ± 7 s versus intermittent 5 s ON/5 s OFF = 69 ± 7 s, all \( P > 0.05 \)).

Irrespective of the mode of stimulus delivery, reflex bradycardic responses (Fig. 4), and their calculated AUC at 5 Hz (Table 2) did not markedly differ. High frequency (15 Hz) continuous stimulation produced the largest reflex bradycardia (Fig. 4) relative to continuous stimulation at 5 Hz and intermittent stimulations at 15 Hz. Intermittent stimulation at 5 and 15 Hz generated similar reductions in HR. Despite numerically larger AUCs for HR, values did not significantly differ within and across frequencies (Table 2).

When ADN stimulation was applied continuously or intermittently at 5 Hz, reflex reduction in MBF (Fig. 5) and calculated AUC (Table 2) remained unaltered. Continuous stimulation at 15 Hz evoked the largest reflex reduction in MBF (Fig. 5) compared with continuous stimulation at 5 Hz and intermittent stimulation at 15 Hz. These findings were not associated with significant differences in AUCs. Likewise, MBF peak and AUC responses to intermittent stimulation at 5 and 15 Hz were relatively comparable.

Calculated reflex reductions in MVR (Fig. 6) in response to stimulation of the ADN at 5 Hz were similar during both continuous and intermittent stimulation. Similarly, when stimulation frequency was increased to 15 Hz peak reductions in MVR (Fig. 6) were comparable during continuous and intermittent stimulation. Across frequencies, continuous stimulation at 15 Hz caused a larger reflex reduction in MVR compared with respective stimulation at 5 Hz (Fig. 6).

Calculated reflex reductions in MVR (Fig. 6) in response to stimulation of the ADN at 5 Hz were similar during both continuous and intermittent stimulations. Similarly, when the stimulation frequency was increased to 15 Hz peak reductions in MVR (Fig. 6) were comparable during continuous and intermittent stimulation. Across frequencies, continuous stimulation at 15 Hz caused a larger reflex reduction in MVR compared with respective stimulation at 5 Hz (Fig. 6).

Calculated reflex reductions in MVR (Fig. 6) in response to stimulation of the ADN at 5 Hz were similar during both continuous and intermittent stimulations. Similarly, when the stimulation frequency was increased to 15 Hz peak reductions in MVR (Fig. 6) were comparable during continuous and intermittent stimulation. Across frequencies, continuous stimulation at 15 Hz caused a larger reflex reduction in MVR compared with respective stimulation at 5 Hz (Fig. 6).

| Parameter | 5 Hz | 15 Hz |
|-----------|------|-------|
|          | Baseline | CONT | 5 s ON/3 s OFF | 5 s ON/5 s OFF | Baseline | CONT | 5 s ON/3 s OFF | 5 s ON/5 s OFF |
| MAP (mmHg) | 171 ± 10 | 143 ± 10* | 146 ± 12* | 141 ± 12* | 170 ± 9 | 117 ± 8* | 136 ± 10* | 134 ± 9* |
| HR (bpm)   | 344 ± 8 | 330 ± 8* | 332 ± 7* | 333 ± 7* | 341 ± 7 | 319 ± 8* | 329 ± 8* | 329 ± 7* |
| MBF (ml min$^{-1}$) | 5.5 ± 0.4 | 4.7 ± 0.4* | 4.8 ± 0.4* | 4.6 ± 0.3* | 5.7 ± 0.4 | 4.2 ± 0.3* | 4.4 ± 0.3* | 4.6 ± 0.3* |
| MVR (mmHg min ml$^{-1}$) | 32 ± 3 | 30 ± 3* | 30 ± 3* | 30 ± 3* | 32 ± 3 | 26 ± 3* | 28 ± 2* | 28 ± 2* |
| FBF (ml min$^{-1}$) | 0.9 ± 0.1 | 1.1 ± 0.1* | 1.1 ± 0.1* | 1.1 ± 0.1* | 0.9 ± 0.1 | 1.3 ± 0.1* | 1.2 ± 0.1* | 1.2 ± 0.1* |
| FVR (mmHg min ml$^{-1}$) | 192 ± 12 | 145 ± 15* | 137 ± 11* | 140 ± 13* | 190 ± 14 | 97 ± 14* | 138 ± 19* | 123 ± 18* |

Table 1. Baseline and peak hemodynamics recorded in response to continuous (CONT) and intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) stimulation of the aortic depressor nerve (ADN) using low (5 Hz) and high (15 Hz) pulse frequencies delivered for 20 s at 0.4 mA and 0.2 ms in pentobarbital-anesthetized spontaneously hypertensive rats. The data are presented as mean ± SEM (n = 8–9) and were analyzed by a two-way ANOVA followed by Bonferroni’s post hoc test. MAP mean arterial blood pressure, HR heart rate, MBF mesenteric blood flow, MVR mesenteric vascular resistance, FBF femoral blood flow, FVR femoral vascular resistance.

$aP < 0.05$ versus respective baseline levels.
Reflex reductions in FVR at 5 Hz (Fig. 8) were similar during continuous or intermittent ADN stimulation. In contrast, maximal reductions in FVR at 15 Hz continuous stimulation (Fig. 8) were significantly greater relative to intermittent stimulation at 15 Hz and continuous stimulation at 5 Hz. Peak FVR responses to intermittent stimulation at 5 and 15 Hz (Fig. 8) as well as measured FVR AUC values across both the 5 and 15 Hz protocols (Table 2) did not markedly differ.
Figure 3. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex reductions in mean arterial pressure (MAP) in pentobarbital-anesthetized spontaneously hypertensive rats. (A, B) The time trend for reflex depressor responses to ADN stimulation, while (C) shows absolute changes (mmHg) in MAP in response to ADN stimulation. Results are expressed as mean ± SEM (n = 9), analyzed by a two-way ANOVA followed by Bonferroni’s post hoc test. a: $P < 0.05$ versus continuous stimulation for each frequency and b: $P < 0.05$ versus respective stimulation across frequencies.

Table 2. Total area under the curve (AUC) for hemodynamic measures recorded in response to continuous (CONT) and intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) stimulation of the aortic depressor nerve (ADN) using low (5 Hz) and high (15 Hz) pulse frequencies delivered for 20 s at 0.4 mA and 0.2 ms in pentobarbital-anesthetized spontaneously hypertensive rats. The data are presented as mean ± SEM (n = 4–9) and were analyzed by a two-way ANOVA followed by Bonferroni’s post hoc test. MAP mean arterial blood pressure, HR heart rate, MBF mesenteric blood flow, MVR mesenteric vascular resistance, FBF femoral blood flow, FVR femoral vascular resistance. a $P < 0.05$ versus continuous stimulation for each frequency. b $P < 0.05$ versus respective stimulation across frequencies.

| Parameter (AUC)  | 5 Hz (CONT) | 5 Hz (5 s ON/3 s OFF) | 5 Hz (5 s ON/5 s OFF) | 15 Hz (CONT) | 15 Hz (5 s ON/3 s OFF) | 15 Hz (5 s ON/5 s OFF) |
|------------------|-------------|-----------------------|-----------------------|-------------|-----------------------|-----------------------|
| MAP (mmHg s)     | 630 ± 148   | 495 ± 114             | 530 ± 122             | 1143 ± 164a | 898 ± 163b           | 794 ± 117a            |
| HR (bpm s)       | 258 ± 111   | 213 ± 57              | 277 ± 125             | 460 ± 99    | 376 ± 108             | 329 ± 104             |
| MBF (ml min⁻¹ s) | 18 ± 5      | 14 ± 3                | 17 ± 4                | 31 ± 7      | 23 ± 6                | 19 ± 6                |
| MVR (mmHg min ml⁻¹ s) | 37 ± 13 | 37 ± 10              | 34 ± 14               | 95 ± 21b    | 74 ± 15              | 94 ± 10b              |
| FBF (ml min⁻¹ s) | 32 ± 4      | 32 ± 4                | 32 ± 4                | 32 ± 4      | 32 ± 4                | 32 ± 4                |
| FVR (mmHg min ml⁻¹ s) | 1085 ± 408 | 1005 ± 316           | 1042 ± 326            | 1402 ± 262  | 1074 ± 331            | 1102 ± 263            |

Figure 4. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex reductions in mean heart rate (HR) in pentobarbital-anesthetized spontaneously hypertensive rats (SHRs). (A, B) The time trend for the reflex bradycardic responses to ADN stimulation, while (C) shows absolute changes (bpm) in HR in response to ADN stimulation. Results are expressed as mean ± SEM (n = 8), analyzed by a two-way ANOVA followed by Bonferroni’s post hoc test. a: $P < 0.05$ versus continuous stimulation for each frequency and b: $P < 0.05$ versus respective stimulation across frequencies.
Discussion
This study supports the concept that aortic baroreceptor afferents may be a viable alternative neuromodulation target to carotid baroreceptors stimulation in lowering ABP. The major finding of the present exploratory study is that in hypertension, modulation of aortic baroreceptor afferent activity in order to drive appreciable and prompt reductions in mesentric blood flow (MBF) in pentobarbital-anesthetized spontaneously hypertensive rats (SHRs). (A,B) The time trend for reflex MBF responses to ADN stimulation, while (C) shows absolute changes (ml min⁻¹) in MBF in response to ADN stimulation. Results are expressed as mean ± SEM (n = 9), analyzed by a two-way ANOVA followed by followed by Bonferroni's post hoc test. a: P < 0.05 versus continuous stimulation for each frequency and b: P < 0.05 versus respective stimulation across frequencies.

Figure 5. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex reductions in mesentric blood flow (MBF) in pentobarbital-anesthetized spontaneously hypertensive rats (SHRs). (A,B) The time trend for reflex MBF responses to ADN stimulation, while (C) shows absolute changes (ml min⁻¹) in MBF in response to ADN stimulation. Results are expressed as mean ± SEM (n = 9), analyzed by a two-way ANOVA followed by followed by Bonferroni's post hoc test. a: P < 0.05 versus continuous stimulation for each frequency and b: P < 0.05 versus respective stimulation across frequencies.

Figure 6. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex reductions in mesentric vascular resistance (MVR) in pentobarbital-anesthetized spontaneously hypertensive rats. (A,B) The time trend for the reflex MVR response to ADN stimulation, while (C) shows absolute changes (mmHg ml min⁻¹) in MVR in response to ADN stimulation. Results are expressed as mean ± SEM (n = 9), analyzed by a two-way ANOVA followed by followed by Bonferroni's post hoc test. b: P < 0.05 versus respective stimulation across frequencies.

It has long been suggested that aortic and carotid baroreceptors and their afferents have different pressure sensitivities, with experimental evidence demonstrating greater mechano-transduction properties of aortic baroreceptor afferents and thus higher-pressure sensitivity than those of carotid baroreceptors. This highlights the possibility that aortic baroreceptors may be an additional and possibly superior interventional target for ABP modulation. However, irrespective of the neuromodulation target, many, if not most, of the published clinical and experimental studies including previous studies from our laboratory assessed reflex cardiovascular responses to baroreflex activation using supramaximal stimulation parameters. Neurophysiologists routinely expose nerves to high stimulation currents/voltages to alter recruitment patterns of A and C fibers when studying various functional aspects of nerves. While this approach defines the whole range of responses a nerve can elicit, generated outcomes are far from physiological and have limited translatability to clinical practice. Despite the
effective and maintained reductions in ABP in response to BAT, the technology is still criticized for the use of ultrahigh stimulation parameters, which increases risk of field stimulation and potential off-target effects, and also impacts nerve structural integrity and promotes nerve fatigue. From a device development perspective, a supramaximal stimulus intensity does very little to inform of a device development pathway with translational applicability and an ultimate goal to treat patients for multiple disease indications. In view of that, a major consideration in this study was to use a neurostimulation model that enabled low energy consumption to characterize the cardiovascular response within it. During our first study, SHRs MAP responses were tested using different low-stimulation-range combinations of pulse intensities (0.2, 0.4 and 0.6 mA), widths (0.1, 0.2 and 0.5 ms) and frequencies (1, 2.5 and 5 Hz), with the aim of providing a clinically acceptable drop in ABP of 20 – 30 mmHg as described by others10,16,25,26.

When stimulated acutely in resistant hypertensive patients, device-based unilateral carotid baroreflex activation was previously shown to evoke more than 20 mmHg reduction in MAP at 4 – 7 V, 20 – 100 Hz, 0.48 ms18. In conscious SHRs, an approximate 30 mmHg drop in MAP was reported with electrical stimulation of the left carotid sinus nerve at 3 V, 30 Hz and 1 ms29. On the other hand, left ADN stimulation at 1 mA, 5 Hz and 2 ms produced an approximate 25 mmHg drop in MAP in conscious L-NAME-induced hypertensive rats, with stimulations beyond 5 Hz resulting in excessive reflex hypotensive responses19. Moreover, a MAP decrease of approximately 30 mmHg in conscious SHRs was attainable when the left ADN was stimulated at 1 mA, 10–15 Hz and 2 ms18. Remarkably, our data reproduced these ABP findings at reduced pulse intensity (0.4 mA) and lower pulse frequency (5 Hz) and/or width (0.2 ms). Our data further demonstrated “no added benefit” for currents

Figure 7. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex increases in femoral blood flow (FBF) in pentobarbital-anesthetized spontaneously hypertensive rats. (A,B) show the time trend for the reflex FBF response to ADN stimulation, while (C) shows absolute changes (ml min⁻¹) in FBF in response to ADN stimulation. Results are expressed as mean ± SEM (n=8), analyzed by a two-way ANOVA followed by followed by Bonferroni’s post hoc test a: P<0.05 versus continuous stimulation for each frequency and b: P<0.05 versus respective stimulation across frequencies.

Figure 8. Effect of (A) low (5 Hz) and (B) high (15 Hz) frequency continuous (CONT) versus intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF) aortic depressor nerve (ADN) stimulation (0.4 mA, 0.2 ms for 20 s) on reflex reductions in femoral vascular resistance (FVR) in pentobarbital-anesthetized spontaneously hypertensive rats. (A,B) show the time trend for the reflex FVR response to ADN stimulation, while (C) shows absolute changes (mmHg ml min⁻¹) in FVR in response to ADN stimulation. Results are expressed as mean ± SEM (n=8), analyzed by a two-way ANOVA followed by followed by Bonferroni’s post hoc test. a: P<0.05 versus continuous stimulation for each frequency and b: P<0.05 versus respective stimulation across frequencies.
findings suggest that it is not necessary to use a high charge injection model to alter afferent traffic within the ADN. Indeed, in previous studies from our laboratory, we have frequently encountered changes in the physical outlook of nerves from bright and translucent to dull and brown because of the intense heat generated by higher pulse amplitudes, longer pulse widths and higher frequencies. From a physiological perspective, such experimental design is often questioned about the quality of data collected at high intensity stimulations, which do not reproduce the natural recruitment pattern of afferent fibers with different pressure thresholds that occur with the spontaneous increases in ABP. The high charge injection model may also represent one of many other factors that underlie the challenges faced in designing longitudinal baroreflex studies and maintaining nerve viability during chronic implant procedures as shown previously in short-term conscious studies in rats. Clinically, selectivity, safety and efficacy issues have often been raised when charge density for BAT was set to higher threshold values. To that end, supramaximal stimulations of the carotid sinus using BAT technology has been shown to alter breath duration and breathing frequency. Jaw or neck pain, swallowing sensation, coughing, or voice problems were also noted by hypertensive patients when BAT employed high stimulation intensities.

In the next series of experiments, we aimed to (1) determine whether the energy required to maintain the ABP decrease in response to ADN stimulation can be minimized even further by delivering the stimulus in an intermittent rather than continuous manner; and (2) assess how altering afferent fibers recruitment pattern by modulating pulse frequency rather than pulse intensity can impact the level of the reflex depressor response. With the intermittent stimulation, a 3 – 5 s OFF period was chosen in order to avoid full recovery of ABP when the stimulus was withdrawn. As far as nerve fibers recruitment are concerned, a low frequency of 5 Hz and a higher one of 15 Hz were chosen since early work from Andersen and colleagues that fibers recruitment in the ADN can be altered by using low-frequency (≤10 Hz) stimulation to engage C-fiber type or high-frequency (>10 Hz) to trigger A-fiber type.

During low frequency stimulation, both intermittent and continuous simulation evoked relatively similar peak hypotensive responses of about 30 mmHg, with both modes of intermittent simulation (5 s ON/3 s OFF and 5 s ON/5 s OFF) likewise generating comparable results. When comparing ABP recovery after both intermittent and continuous stimulation, responses were similarly sustainable throughout the stimulation window as evidenced by the comparable AUC measures and recovery time for intermittent and continuous MAP responses. Reflex bradycardic and vascular resistance responses to low frequency stimulation mirrored those of BAT, suggesting that the comparable reflex depressor responses to both intermittent and continuous stimulation were potentially driven by the similar reflex changes in HR and vascular resistance. Importantly, these results indicate that a clinically relevant drop in ABP can be evoked by solely engaging C-fiber afferents and that energy consumption during stimulation cannot only be minimized using a low charge injection system but also through intermittent delivery of the electrical stimulus.

Recruitment of A-fiber type using higher frequency stimulation induced larger immediate drops in ABP (approximately 50 mmHg), HR, MVR and FVR, however this was only apparent when the stimulus was applied continuously. Irrespective of the OFF period, intermittent high frequency stimulation, lowered the excessive reductions in ABP, HR and vascular resistances encountered with the continuous stimulation, suggesting that intermittent high frequency stimulation offers a less drastic impact on cardiovascular responses than continuous stimulation. Indeed, a major concern with large immediate reductions in ABP is the resulting hemodynamic instability that can occur with baroreflex activation, which is a leading cause for impaired organ perfusion. The ABP responses to both modes of intermittent high frequency stimulation were slightly, but significantly higher and more sustained than the corresponding low frequency stimulation. This indicates that intermittent high frequency stimulation may be sought after if an additional reduction in ABP is required. Importantly, when compared to the corresponding responses to low frequency stimulation, the significant ABP responses to intermittent high frequency stimulation were not mirrored by similarly large changes in the other recorded hemodynamic variables. It is well known that changes in peripheral vascular resistance are the primary contributor to changes in ABP and while the recorded HR and vascular resistance responses would have, at least partly, prompted this ABP response, the current data suggest the involvement of some unexplored vascular beds in this study, which could have similarly contributed to the overall reduction in systemic vascular resistance in response to the stimulation.

Of note was the finding that the hemodynamic responses to 15 Hz stimulations, but less so with 5 Hz stimulations, were trending back toward baseline level particularly when the stimulus was applied intermittently. It is known that the A-type baroreceptor afferents alone are capable of separately producing 70 – 80% of the combined maximal MAP response. It is therefore possible that high frequency intermittent volleys, when delivered briefly (5 s) during the ON period, were unable to achieve maximal activation of the A-type fibers, resulting in a lower blood lowering efficacy. Alternatively, the hemodynamic response pattern with high frequency may suggest that the ascendingafferent activity is limited, leading to blood pressure lowering. The ABP response to intermittent high frequency stimulation were similarly sustainable throughout the stimulation window as evidenced by the comparable AUC measures and recovery time for intermittent and continuous MAP responses. The ABP responses to both modes of intermittent high frequency stimulation were slightly, but significantly higher and more sustained than the corresponding low frequency stimulation. This indicates that intermittent high frequency stimulation may be sought after if an additional reduction in ABP is required. Importantly, when compared to the corresponding responses to low frequency stimulation, the significant ABP responses to intermittent high frequency stimulation were not mirrored by similarly large changes in the other recorded hemodynamic variables. It is clear that changes in peripheral vascular resistance are the primary contributor to changes in ABP and while the recorded HR and vascular resistance responses would have, at least partly, prompted this ABP response, the current data suggest the involvement of some unexplored vascular beds in this study, which could have similarly contributed to the overall reduction in systemic vascular resistance in response to the stimulation.

A limitation of this study was the recording of hemodynamic responses to ADN stimulation under anesthesia. Surgical anesthesia is often criticized for its unfavorable impact on cardiovascular and autonomic reflexes, and thus the use of conscious studies enables recording of cardiovascular variables with a higher fidelity. However, success of conscious longitudinal baroreflex studies using the ADN in rats is currently low and hampered by (1) inherent anatomical challenges given the small diameter of the nerve and the relative ease to sustain a damage to it during dissection and manipulation; and (2) the use of unrefined electrode design and nerve stimulation protocols that can ensure long-term viability of the nerve. To our knowledge, current studies reporting hemodynamic responses to ADN stimulation in conscious rats are typically run within 24 h after surgical implantation of the electrodes. It is therefore possible that reported measures by those studies may, to a great extent, be
confounded by issues related to surgical stress and inadequate animal recovery. Therefore, in order to ensure successful transition to conscious baroreflex studies, future research work should address these challenges.

A second limitation was the use of pentobarbital for induction and maintenance of anesthesia, an anesthetic known to evoke a greater suppression of hypothalamic cardiovascular regulation and baroreflex reinforcement\(^2\) relative to other forms of anesthesia including urethane and inhalation anesthetics. While urethane\(^3\) and inhalation anesthetics (e.g., isoflurane, sevoflurane or enflurane)\(^4\) have less impact on baroreflex control, owing to their considerable reduction of sympathetic contribution to ABP maintenance\(^5\), they seem to overly lower baseline blood pressure levels in the SHRs, with values almost approaching the normotensive range\(^6\). In our hands (despite titrating urethane or isoflurane to the lowest effective dose), our SHRs, when maintained on these anesthetics, had MAP levels ranging between 80 and 100 mmHg (data not shown). These readings do not reflect the hypertensive state of the SHRs and also defeat the purpose of the model and the research question from this study. It is well known that recruitment pattern of individual baroreceptor fibers and baroreflex resetting, which can occur almost instantaneously\(^7\), are tied to baseline blood pressure levels and can alter the magnitude of responses to baroreflex activation. We therefore believe that low MAP baseline and resultant changes in baroreflex function were major disqualifiers for urethane and isoflurane as choices of anesthesia in the SHRs. With pentobarbital, on the other hand, baseline MAP levels were not only preserved but also matched those reported in conscious SHRs\(^8\). Importantly, pentobarbital anesthesia appears to influence baroreflex control of heart rate mainly through impairing reflex cardiac parasympathetic activity\(^9\). This also leaves reflex sympathetic control of vascular resistance, the primary determinant of blood pressure control\(^1\), unaffected, suggesting a relative reliability of hemodynamic data generated under pentobarbital anesthesia and other barbiturate anesthetics as shown previously\(^1\).

A third limitation of the current study is that hemodynamic responses to ADN stimulation were tracked briefly and thus further studies, perhaps in a reliable chronic setup, are required to assess MAP adaptation to the applied stimulus. However, based on our current findings in hypertension and those reported by others in normotensive rats\(^1\), we believe that sustaining a reduction in blood pressure following the withdrawal of the electrical stimulus is unlikely. Whether longer stimulations can result in a baseline shift in MAP remains unclear. Preliminary evidence at least in conscious normotensive rats argues against this possibility\(^5\), mirroring our data by demonstrating a similar rebound in the blood pressure response toward baseline despite using a higher frequency (30 Hz) and longer stimulation protocol (60 min). However, whether different findings can be identified under hypertensive conditions remains to be determined. In the light of the above evidence, we believe that targeting the recruitment pattern of A-type versus C-type fibers during stimulation carries a huge potential to identify optimal stimulation parameters that can evoke a maintained drop in blood pressure. Indeed, the low frequency protocol described here offer a more consistent drop in blood pressure, with a minimal rebound seen irrespective of the continuous or intermittent mode of stimulus delivery. This indicates that low-frequency protocols (< 10 Hz) targeting the C-fiber afferents may potentially offer a more robust and sustainable drop in blood pressure in the long term as opposed to high-frequency stimulation protocols that predominantly recruit A-fiber afferents.

Finally, it can be argued that the use of rectangular impulses in our experiments may have affected nerve viability and thus skewed the data generated from the stimulation protocol. We, however, strongly believe that such possibility is quite unlikely due to 3 main reasons: (1) the short nature of our stimulations significantly lowered nerve exposure to the rectangular pulses; (2) the stimulation protocol itself implemented low charge injections with ultralow stimulation parameters; and (3) during physical inspection of the nerve throughout the experiments no gross changes in the physical outlook of the nerve was seen as the nerve maintained its bright and translucent appearance.

**Perspectives**

Research on carotid baroreflex activation and the fundamental implementation of this technique as a treatment modality for hypertension has come a long way since 1958\(^3\). Over the past 20 years, substantial attention has been given to the Rheo Hypertension Therapy System and most recently, the Barostim Neo System, which proved effective in chronically suppressing sympathetic activity and lowering ABP. While this approach is strongly supported by experimental and clinical studies, critical endpoints for efficacy and safety have yet to be achieved, necessitating modifications in device technology and the design of better testing protocols. Current clinical research data pertaining to “carotid” BAT still report some variability in the ABP response across patients and the procedure is often criticized for concomitant chemoreflex activation especially when approaching higher stimulations\(^3\). This off-target action is believed to (1) reduce the ABP lowering efficacy of BAT in some patients given the sympathetic stimulation associated with chemoreflex activation\(^3\), and (2) underlie reported breathing adverse effects associated with the procedure\(^3\). This calls for reassessment of current BAT stimulation protocols to fine-tune them, or alternatively seeking other potential ABP modulation targets and analyzing their response pattern. Our study emphasizes the significance of “aortic” baroreceptor afferent nerves as a prospective target and extends beyond that to show how low intensity stimulation is an effective alternate way to modulate afferent traffic within baroreceptor neurons that enables low energy consumption for neuromodulation. We believe that these results will open new exploratory avenues for translational research within this field and will help guide future practices relating to the selection of stimulation parameters for the baroreceptor afferents studies in human and experimental animals.
Materials and methods

Animals. All surgical procedures and experimental protocols strictly followed National Institute of Health (NIH) guidelines, were approved by the Institutional Animal Care and Use Committee of Case Western Reserve University and were in accordance with the recommendations in the ARRIVE guidelines ([https://arriveguidelines.org](https://arriveguidelines.org/)). Adult male SHRs (n = 13, body weight = 320–390 g) were sourced from Envigo (Indianapolis, IN, USA). Four SHRs were used in Study 1, which aimed to optimize the neurostimulation parameters and the magnitude of ABP drop. A second cohort of 9 SHRs was used in Study 2, which aimed to assess cardiovascular responses to continuous and intermittent nerve stimulation. Rats were kept under controlled temperatures (22 °C) and constant 12:12 h light–dark cycle and received food and water ad libitum.

Surgical procedure. All rats were anesthetized with an intraperitoneal injection of 50 mg kg⁻¹ of sodium pentobarbital (Diamondback, Arizona, USA) and the depth of anesthesia was evaluated by testing withdrawal reflexes to toe pinch before initiating any surgery. Core body temperature was maintained using a thermostatically controlled heating blanket (T/Pump warm water re-circulator, Stryker Medical, Michigan, USA). The right femoral artery was catheterized to record ABP, and the right femoral vein was cannulated to deliver a continuous infusion (Harvard Apparatus Ltd., Massachusetts, USA) of the maintenance anesthetic (10 mg kg⁻¹ h⁻¹ of pentobarbital sodium in saline administered at 2 ml h⁻¹). A ventral neck incision was made to expose the trachea and the left ADN. A tracheotomy was performed to facilitate spontaneous breathing. A 4–6 mm segment of the ADN was isolated distal to the point where it entered the superior laryngeal nerve and placed on bipolar silver-wire stimulating electrodes (inter-electrode distance of approximately 1 mm) and maintained uncult in mineral oil, as described previously.²⁷,²⁸,⁴⁷. The stimulating electrodes were then connected to a square pulse stimulator (S88 Dual Output Square Pulse Stimulator, Grass Technologies Product Group, Wisconsin, USA) using a stimulus isolation unit (Grass Instrument Co. Model PSIU6 Photoelectric Stimulus Isolation Unit, Grass Technologies Product Group, USA) to deliver monophasic electrical current. All corresponding voltage traces were recorded using a digital oscilloscope (Yokogawa Digital Oscilloscope DL708E, Tokyo, Japan).

In some rats (Study 2), the superior mesenteric artery and the left femoral artery were dissected free and a clip-on-type flow probe (TS420 Perivascular Flow Module, Transonic Systems Inc., New York, USA) was placed around them for continuous concomitant recording of mesenteric and femoral blood flow from both vascular beds. All recordings were acquired using CED 1401 data acquisition system (Power3A CED 1401, Cambridge Electronic Designs Ltd., Cambridge, UK) and displayed on the computer using Spike2 software (v8, Cambridge Electronic Designs Ltd.). At the end of the surgical procedure, animals were allowed to stabilize for 15–30 min before commencing experimental protocols.

Experimental protocol

Study 1. Peak MAP responses elicited by 20 s stimulations of the left ADN delivered continuously using low pulse amplitudes (0.2, 0.4 and 0.6 mA), widths (0.1, 0.2 and 0.5 ms) and frequencies (1, 2.5 and 5 Hz) were recorded. MAP was allowed to return to baseline pre-stimulus levels for 2–3 min before application of the next stimulus.

Study 2. The changes in MAP, heart rate (HR), mesenteric blood flow (MBF) and femoral blood flow (FBF) in response to continuous (20 s) and intermittent (5 s ON/3 s OFF and 5 s ON/5 s OFF for 20 s) stimulation of the ADN were recorded at low (5 Hz) and high (15 Hz) pulse frequencies and with all stimulations delivered at 0.4 mA and 0.2 ms. All variables were allowed to return to baseline pre-stimulus levels for 2 – 3 min before applying the next stimulus.

Data analysis. MAP and HR were derived from the arterial pressure waveform. Calculation of mesenteric (MVR) and femoral (FVR) vascular resistance were performed using the following equation.

\[
\text{Vascular Resistance (mmHg min ml}^{-1}) = \frac{\text{MAP (mmHg)}}{\text{Blood Flow (ml min}^{-1})}
\]

Baseline MAP, HR, MBF, FBF, MVR and FVR were measured over a 40 s period immediately prior to commencing the stimulation protocol. All reflex hemodynamic responses to ADN stimulation were converted into 5 s bins and plotted against time as 40 s baseline and 80 s from when the stimulus was applied. Absolute changes in MAP, HR, MBF, FBF, MVR and FVR were then calculated by measuring the peak changes in response relative to the immediate 40 s baseline prior to the application of each electrical stimulus. MAP recovery time was calculated as the time between the start of the stimulation and the time when the response was back to no more than 5% of baseline levels. Areas under the curve (AUC), reflective of the sustainability of the responses, were also calculated over a 40 s period from the start of stimulation.

Statistics. All data are expressed as mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism software (v8, GraphPad Prism Inc., La Jolla, California, USA). A two-way ANOVA followed by Bonferroni correction for multiple comparisons between means was used to identify differences in basal values, peak responses, and AUC measures. Significance was defined as P ≤ 0.05.

Data availability
Due to confidentiality agreements, the datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References

1. World Health Organization. World Health Statistics 2021: Monitoring Health for the SDGs, Sustainable Development Goals. Licence: CC BY-NC-SA 3.0 IGO. (World Health Organization, 2021).

2. Bogle, B. M., Ning, H., Mehrrota, S., Goldberger, J. J. & Lloyd-Jones, D. M. Lifetime risk for sudden cardiac death in the community. J. Am. Heart Assoc. 5, 002398 (2016).

3. Yoon, S. S., Carroll, M. D. & Fryar, C. D. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief 220, 1–8 (2015).

4. Whelton, P. K. et al. ACC/AHA/ASCN/MMT/AAPA/ASPC/NAAPA/AMER/SCA/ACAP guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary. Rep. Am. Coll. Cardiol./Am. Heart Assoc. Task Force Clin. Pract. Guidelines https://doi.org/10.1161/hyp.0000000000000666 (2017).

5. Doumas, M. et al. Carotid baroreceptor stimulation: A promising approach for the management of resistant hypertension and heart failure. Curr. Vasc. Pharmacol. 12, 30–37 (2016).

6. Dampney, R. A. Functional organization of central pathways regulating the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 29, 261–268 (2002).

7. Dampney, R. A. et al. Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 29, 261–268 (2002).

8. Salman, I. M. Current approaches to quantifying tonic and reflex autonomic outflows controlling cardiovascular function in humans and experimental animals. Curr. Hypertens. Rep. 17, 015–0397 (2015).

9. Heusser, K. et al. Acute response to unilateral unipolar electrical carotid sinus stimulation in patients with resistant arterial hypertension. Hypertension 67, 585–591 (2016).

10. Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619–626 (2010).

11. Lohmeier, T. E., Irwin, E. D., Rossing, M. A., Serdar, D. J. & Kieval, R. S. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 43, 306–311 (2004).

12. Bakris, G. L. et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: Results of long-term follow-up in the Rheos Pivotal Trial. J. Am. Soc. Hypertens. 6, 152–158 (2012).

13. Bisognano, J. D. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J. Am. Coll. Cardiol. 58, 765–773 (2011).

14. Hoppe, U. C. et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: Results from the Barostim neo trial. J. Am. Soc. Hypertens. 6, 270–276 (2012).

15. Wallbach, M. et al. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension. J. Hypertens. 36, 1762–1769 (2018).

16. Katayama, P. L. et al. Hypertension. Vol. 66, 598–603. (2015).

17. Salgado, H. C. et al. Baroreflex responses to electrical stimulation of aortic depressor nerve in conscious SHR. Am. J. Physiol. Heart Circ. Physiol. 292, H593–600. https://doi.org/10.1152/ajpheart.00181.2006 (2007).

18. Durand Mde, T., Castania, J. A., Fazan, R. Jr., Salgado, M. C. & Salgado, H. C. Hemodynamic responses to aortic depressor nerve stimulation in conscious L-NAME-induced hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, 24 (2011).

19. Mohaupt, M. G., Schmidli, J. & Luft, F. C. Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension 50, 825–827 (2007).

20. Glick, G. & Covell, J. Relative importance of the carotid and aortic baroreceptors in the reflex control of heart rate. Am. J. Physiol.-Legacy Content 214, 955–961 (1968).

21. Lai, E. O. et al. Aortic baroreceptors display higher mechanosensitivity than carotid baroreceptors. Front. Physiol. 7, 384 (2016).

22. Pickering, A. E., Simms, A. E. & Paton, J. F. Dominant role of aortic baroreceptors in the cardiac baroreflex of the rat in situ. Auton. Neurosci. 142, 32–39. https://doi.org/10.1016/j.autneu.2008.03.009 (2008).

23. Fan, W., Reynolds, P. J. & Andresen, M. C. Baroreflex frequency-response characteristics to aortic depressor and carotid sinus nerve stimulation in conscious L-NAME induced hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, 24 (2011).

24. Pickering, A. E., Simms, A. E. & Paton, J. F. Dominant role of aortic baroreceptors in the cardiac baroreflex of the rat in situ. Auton. Neurosci. 142, 32–39. https://doi.org/10.1016/j.autneu.2008.03.009 (2008).

25. Fan, W., Reynolds, P. J. & Andresen, M. C. Baroreflex frequency-response characteristics to aortic depressor and carotid sinus nerve stimulation in conscious L-NAME induced hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, 24 (2011).

26. Pickering, A. E., Simms, A. E. & Paton, J. F. Dominant role of aortic baroreceptors in the cardiac baroreflex of the rat in situ. Auton. Neurosci. 142, 32–39. https://doi.org/10.1016/j.autneu.2008.03.009 (2008).

27. Fan, W., Schild, J. H. & Andresen, M. C. Graded and dynamic reflex summation of myelinated and unmyelinated rat aortic baroreceptors. Am. J. Physiol. Heart Circ. Physiol. 297, H402-409. https://doi.org/10.1152/ajpheart.00181.2010 (2010).

28. Domingos-Souza, G. et al. The ability of baroreflex activation to improve blood pressure and resistance vessel function in spontaneously hypertensive rats is dependent on stimulation parameters. Hypertens. Res. Off. J. Jpn. Soc. Hypertens. 44, 932–940. https://doi.org/10.1007/s10992-021-00639-9 (2021).

29. Alnima, T. et al. Baroreflex activation therapy lowers arterial pressure without apparent stimulation of the carotid bodies. Hypertension 65, 1217–1222. https://doi.org/10.1161/hypertensionaha.114.04354 (2015).

30. Fan, W. & Andresen, M. C. Differential frequency-dependent reflex integration of myelinated and nonmyelinated rat aortic baroreceptors. Am. J. Physiol. 275, H632–640 (1998).

31. Fan, W., Schild, J. H. & Andresen, M. C. Graded and dynamic reflex summation of myelinated and unmyelinated rat aortic baroreceptors. Am. J. Physiol. 277, R748-756 (1999).

32. Simmons, J. P. & Wohl, J. S. Small Animal Critical Care Medicine (eds. Silverstein, D.C. & Hopper, K.). 27–30. (W.B. Saunders, 2009).

33. Carroll, R. G. Cardiovascular pressure-flow relationships: What should be taught? Adv. Physiol. Educ. 25, 80–86 (2001).

34. Chappeau, M. W., Hadzuczkog, G. & Abboud, F. M. Mechanisms of resetting of arterial baroreceptors: An overview. Am. J. Med. Sci. 295, 327–334 (1988).

35. Durand, M. et al. Time course of the hemodynamic responses to aortic depressor nerve stimulation in conscious spontaneously hypertensive rats. Braz. J. Med. Biol. Res. 45, 444–449. https://doi.org/10.1590/s0100-879x2012070300032 (2012).

36. Price, H. L. General anesthesia and circulatory homeostasis. Physiol. Rev. 40, 187–218. https://doi.org/10.1152/physrev.1960.40.2.187 (1960).

37. Barringer, D. L. & Buňag, R. D. Differential anesthetic depression of chronotropic baroreflexes in rats. J. Cardiovasc. Pharmacol. 15, 10–15. https://doi.org/10.1097/00005344-199010000-00002 (1990).
39. Murakami, M. et al. Inhalation anesthesia is preferable for recording rat cardiac function using an electrocardiogram. *Biol. Pharm. Bull.* **37**, 834–839. https://doi.org/10.1248/bpb.b14-00012 (2014).

40. Bencze, M., Behulaik, M. & Zicha, J. The impact of four different classes of anesthetics on the mechanisms of blood pressure regulation in normotensive and spontaneously hypertensive rats. *Physiol. Res.* **62**, 471–478. https://doi.org/10.3354/physiolres.932637 (2013).

41. Kubota, Y. et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. *Biol. Pharm. Bull.* **29**, 1756–1758. https://doi.org/10.1248/bpb.29.1756 (2006).

42. Watkins, L. & Maixner, W. The effect of pentobarbital anesthesia on the autonomic nervous system control of heart rate during baroreceptor activation. *J. Auton. Nerv. Syst.* **36**, 107–114. https://doi.org/10.1016/0165-1838(91)90106-d (1991).

43. Seagard, J. L., Gallenberg, L. A., Hopp, F. A. & Dean, C. Acute resetting in two functionally different types of carotid baroreceptors. *Circ. Res.* **70**, 559–565. https://doi.org/10.1161/01.res.70.3.559 (1992).

44. Vayssettes-Courchay, C., Melka, J., Philouze, C. & Harouki, N. Sympathetic nerve activity and baroreflex are strongly altered in a context of severe hypertension using the spontaneously hypertensive rat model associated with chronic reduction of nitric oxide. *Int. J. Hypertens.* **2021**, 4808657. https://doi.org/10.1155/2021/4808657 (2021).

45. Brognara, F. et al. Cardiovascular responses elicited by continuous versus intermittent electrical stimulation of the aortic depressor nerve in conscious rats. *Life Sci.* **148**, 99–105 (2016).

46. Carlsten, A., Folkow, B., Grimby, G., Hamberger, C. A. & Thulesius, O. Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. *Acta Physiol. Scand.* **44**, 138–145 (1958).

47. Salman, I. M. et al. Laterality influences central integration of baroreceptor afferent input in male and female Sprague Dawley rats. *Front. Physiol.* **11**, 499 (2020).

48. Borne, A. T., Truett, A. A., Monteiro, M. P., Volaufova, J. & West, D. B. Changes in skeletal muscle vascular resistance with weight gain: Associations with insulin and sympathetic activity. *Obes Res* **7**, 68–75 (1999).

**Acknowledgements**

All authors would like to express their gratitude to Ms. Melissa Dusek and to Dr. Paulina Getsy for their excellent technical assistance with the study.

**Author contributions**

I.S. contributed to the design of the research, performed experiments, analyzed data, interpreted results of experiments, prepared figures, drafted the manuscript, and approved and submitted the final version of manuscript. O.A. assisted in the performance of experiments and data collection and approved the final version of manuscript. S.M., S.H., A.S., S.L. and Y.-H.H. contributed to the design of research and revised and approved final version of manuscript.

**Funding**

The study was supported by Galvani Bioelectronics-GlaxoSmithKline (Grant number: GGSK-1004).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to I.M.S.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022